Therefore, CD3+/CD8+ CTLs and CD3+/CD56+ NKT cells can facilitate tumor cell damage cooperatively as a CTL-NKT circuit, in accordance with the bet-hedging strategy (Fig. 5C). The gene discussed is NCAM1; the disease is neoplasm.